Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Oculis closes CHF20mm Series B round; adds CHF15.5mm

Executive Summary

Oculis raised CHF20mm ($20.3mm) through its Series B financing to new backers Bay City Capital, Novartis Venture Fund, and Pivotal bioVenture Partners and returning shareholders Brunnur Ventures and Silfurberg. The company will use the funds for ongoing development of its lead compound OC118, which is in Phase IIb for diabetic macular edema. Proceeds will also be used to develop OC118 for other indications and for development of additional candidates that incorporate the firm's solubilizing nanoparticle (SNP) technology. Representatives from Bay City Capital, Novartis Venture Fund, Pivotal bioVenture, and Brunnur Ventures will take board seats.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies